DiscGenics received FDA Fast Track designation for its investigational cell therapy for the reduction in pain and disability linked with degenerative disc disease.
Three insights:
1. IDCT is an injectable cell therapy that use progenitor cells — known as Discogenic Cells — to provide a regenerative solution for the treatment of mild to moderate degenerative disc disease.
2. Its biomedically engineered progenitor cells are derived from intervertebral disc tissue and offer a non-invasive approach to treating the condition.
3. IDCT is currently being evaluated in clinical trials in the U.S. and Japan.